Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12033401 | 1.00 | ATM (0.60) | ATMPPARGCTSLCTSSCYP2D6 | |
| SCHEMBL12033400 | 1.00 | ATM (0.60) | ATMPPARGCTSLCTSSCYP2D6 | |
| SCHEMBL1362502 | 0.86 | ATM (0.77) | ATMPPARGCTSLCTSSCYP2D6 | |
| SCHEMBL434233 | 0.86 | ATM (0.77) | ATMPPARGCTSLCTSSCYP2D6 | |
| SCHEMBL7719287 | 0.86 | ATM (0.77) | ATMPPARGCTSLCTSSCYP2D6 | |
| SCHEMBL3255533 | 0.86 | ATM (0.77) | ATMPPARGCTSLCTSSCYP2D6 | |
| SCHEMBL28224944 | 0.85 | ATM (0.64) | ATMCTSLCTSSCYP2D6CYP2C9 | |
| SCHEMBL28224943 | 0.85 | ATM (0.64) | ATMCTSLCTSSCYP2D6CYP2C9 | |
| SCHEMBL16766403 | 0.84 | ATM (0.62) | ATMPPARGCTSLCTSS | |
| SCHEMBL9457091 | 0.82 | ATM (0.76) | ATMPPARGCTSLCTSSCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312996-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312996-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011146401-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312996-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, PYGL | ATM 4334/4885PPARG 3646/4885CTSL 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.